Clinical observation on the removal of donor specific antibody by double filtration plasmapheresis in renal transplant recipients
-
摘要:
目的 探讨双重膜滤过式血浆置换(DFPP)对高致敏肾移植受者的供体特异性抗体(DSA)的清除效果。 方法 4例肾移植高致敏受者共进行了7例次DFPP治疗,采用Luminex技术监测DSA的变化,观察治疗效果、急性排斥反应发生情况及其不良反应。 结果 治疗后DSA的MFI [1 036(0~4 113)]较治疗前[6 446(2 999~12 905)]明显下降(Z=-2.503,P=0.012)。4例高致敏肾移植受者均未发生超急性排斥反应,仅有1例发生急性排斥反应且通过术后DFPP治疗及调整免疫抑制剂得到逆转。受者随访至今移植肾功能良好,未发生排斥反应。DFPP治疗引起白蛋白水平下降。 结论 DFPP可以有效清除受者体内的DSA,可以安全、有效地预防高致敏人群肾移植术后急性排斥反应。 -
关键词:
- 双重膜滤过式血浆置换 /
- 肾移植 /
- 供体特异性抗体(DSA) /
- 受者,高致敏 /
- 抗体介导的排斥反应(AMR) /
- Luminex技术 /
- 人类白细胞抗原(HLA)抗体 /
- 白蛋白
Abstract:Objective To investigate the effect of double filtration plasmapheresis (DFPP) upon the removal of donor specific antibody (DSA) in highly sensitized recipients with renal transplantation. Methods Four highly sensitized recipients undergoing renal transplantation received 7 cycles of DFPP. Luminex technology was adopted to monitor the changes of DSA. Clinical efficacy, incidence of acute rejection and adverse reactions were observed. Results After DFPP, the DSA MFI [1 036 (0-4 113)] was significantly declined than that before treatment [6 446 (2 999-12 905), Z=-2.503, P=0.012]. No hyperacute rejections occurred in four highly sensitized recipients undergoing renal transplantation. Acute rejection was noted in one case, which was mitigated by postoperative DFPP and adjustment of immunosuppressive agents. During postoperative follow-up, the function of transplant kidney was normal and no rejection reactions occurred. The level of albumin was decreased after DFPP. Conclusions DFPP can effectively remove the DSA in the recipients. It is an efficacious and safe approach to prevent the incidence of acute rejections in highly sensitized recipients after renal transplantation. -
表 1 4例受者的DSA特异性分析及其对应供者的HLA基因分型
Table 1. DSA specificity analysis of 4 recipients and HLA genotype of corresponding donors
例序 受者DSA 供者HLA基因分型 1 A24(9),DQ5 A[2, 24(9)],B(60, 60),DR(16, 16),DQ[5(1), 5(1)] 2 DR16,DRw51 A(1101, 1101),B(13, 60),DR(16, 16),DRw(51, 51),DQ[(5(1), 5(1)] 3 A2,DR15(2),DQ6(1),DQ9(3),DR51,DR53 A(1, 2),B(46, 52),DR(9, 15),DRw(53, 51) 4 A2,DR15(2),DRw51,DQ6(1),DQ7(3) A(1101, 2),B(75, 58),DR(15, 12),DRw(51, 52),DQ[7(3), 6(1)] 表 2 4例受者7例次DFPP治疗前后免疫球蛋白和补体的变化
Table 2. Changes of immunoglobulin and complement in 4 recipients before and after DFPP treatment
[M(Q), g/L] 指标 治疗前(n=7) 治疗后(n=7) Z值 P值 IgG 14.71(9.63~18.62) 3.32(2.87~4.86) -3.981 0.001 IgA 2.88(1.48~3.89) 0.50(0.21~1.63) -2.958 0.003 IgM 0.99(0.75~2.50) 0.22(0.17~1.16) -2.113 0.035 C3 1.03(0.75~1.32) 0.37(0.32~0.77) -2.958 0.003 C4 0.32(0.14~0.52) 0.07(0.01~0.12) -2.551 0.011 -
[1] Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts[J]. Curr Opin Organ Transplant, 2014, 19(3): 315-322. DOI: 10.1097/MOT.0000000000000072. [2] Delville M, Charreau B, Rabant M, et al. Pathogenesis of non-HLA antibodies in solid organ transplantation: where do we stand?[J]. Hum Immunol, 2016, 77(11): 1055-1062. DOI: 10.1016/j.humimm.2016.05.021. [3] Wiebe C, Nevins TE, Robiner WN, et al. The synergistic effect of class Ⅱ HLA epitope-mismatch and nonadherence on acute rejection and graft survival[J]. Am J Transplant, 2015, 15(8): 2197-2202.DOI: 10.1111/ajt.13341. [4] 朱兰, 陈刚, 谢林, 等.肾移植术后新生HLA-DQ抗体的临床意义[J].中华医学杂志, 2014, 94(42): 3284-3288. DOI: 10.3760/cma.j.issn.0376-2491.2014.42.002.Zhu L, Chen G, Xie L, et al. Role of de novo HLA-DQ antibodies in renal transplantation: analysis of a single center data[J]. Natl Med J China, 2014, 94(42): 3284-3288. DOI: 10.3760/cma.j.issn.0376-2491.2014.42.002. [5] Wanner C, Tonelli M. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient[J]. Kidney Int, 2014, 85(6): 1303-1309.DOI: 10.3760/cma.j.issn.0254-1785.2011.10.005. [6] 李雪, 文吉秋.移植肾抗体介导的排斥反应的诊治新进展[J].肾脏病与透析肾移植杂志, 2015, 24(5): 481-486. http://d.wanfangdata.com.cn/Periodical/szbytxsyzzz201505018Li X, Wen JQ. Antibody-mediated rejection in kidney transplantation: diagnosis and management[J]. Chin J Nephrol Dial Transplant, 2015, 24(5): 481-486. http://d.wanfangdata.com.cn/Periodical/szbytxsyzzz201505018 [7] 王宁, 李卫, 张盛.肾移植术前供者特异性抗体强度对术后的体液排斥反应和移植物功能的影响[J].中南大学学报(医学版), 2016, 41(5): 513-519. DOI: 10.11817/j.issn.1672-7347.2016.05.011.Wang N, Li W, Zhang S. Effect of pre-transplant donor specific antibody on antibody-mediated rejection and graft dysfunction[J]. J Cent South Univ(Med Sci), 2016, 41(5): 513-519. DOI: 10.11817/j.issn.1672-7347.2016.05.011. [8] Devos JM, Gaber AO, Teeter LD, et al. Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection[J]. Transplantation, 2014, 97(5): 534-540. DOI: 10.1097/01.TP.0000438196.30790.66. [9] Salvadori M, Bertoni E. Impact of donor-specific antibodies on the outcomes of kidney graft: pathophysiology, clinical, therapy[J]. World J Transplant, 2014, 4(1): 1-17. DOI: 10.5500/wjt.v4.i1.1. [10] 林华, 陈洁晶, 陈怀周, 等.Luminex技术监测抗HLA抗体对肾移植受者预后的影响[J].器官移植, 2016, 7(5): 386-389. DOI: 10.3969/j.issn.1674-7445. 2016.05.011.Lin H, Chen JJ, Chen HZ, et al. Effect of anti-HLA antibody detected by Luminex testing on clinical prognosis of renal transplantation recipients[J]. Organ Transplant, 2016, 7(5): 386-389. DOI: 10.3969/j.issn.1674-7445. 2016.05.011. [11] Smith RN, Colvin RB. Chronic alloantibody mediated rejection[J]. Semin Immunol, 2012, 24(2): 115-121.DOI: 10.1016/j.smim.2011.09.002. [12] Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review[J]. Transplantation, 2012, 94(8): 775-783. DOI: 10.1097/TP.0b013e31825d1587. [13] 张洪宪, 赵磊, 侯小飞, 等.血浆置换治疗肾移植术后抗体介导的急性排斥反应的疗效观察[J].中华泌尿外科杂志, 2015, 36(1): 20-23. DOI: 10.3760/cma.j.issn.1000-6702.2015.01.005.Zhang HX, Zhao L, Hou XF, et al. Application of plasmapheresis in treating the antibody-mediated acute rejection after kidney transplantation[J]. Chin J Urol, 2015, 36(1): 20-23. DOI: 10.3760/cma.j.issn.1000-6702.2015.01.005. [14] Tydén G, Kumlien G, Efvergren M. Present techniques for antibody removal[J]. Transplantation, 2007, 84(12 Suppl): S27-S29. DOI: 10.1097/01.tp.0000296102.94695.c0. [15] Jordan SC. Donor-specific HLA antibody IgG subclasses are associated with phenotypes of antibody-mediated rejection in sensitized renal allograft recipients[J]. J Am Soc Nephrol, 2016, 27(1): 6-8. DOI: 10.1681/ASN.2015060608.
计量
- 文章访问数: 136
- HTML全文浏览量: 73
- PDF下载量: 15
- 被引次数: 0